報價延遲最少15分鐘:2025/01/21 08:47 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
-- 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.13/-0.30
|
|
企業價值
90.33M
|
| 資產負債 |
|
每股賬面淨值
0.33
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
91.30M
|
|
每股收益
0.49
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/01/21 08:47 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products includeOsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the US. |